Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.64 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6216313 | 0.98 | HSD17B10 (0.62) | HSD17B10GABRA5GABRB2ALDH1A1SMN1; SMN2 | |
| SCHEMBL27562636 | 0.84 | GABRA5 (0.66) | HSD17B10GABRA5GABRB2ALDH1A1SMN1; SMN2 | |
| SCHEMBL10995026 | 0.83 | HSD17B10 (0.60) | HSD17B10GABRA5GABRB2ALDH1A1SMN1; SMN2 | |
| SCHEMBL27742441 | 0.83 | GABRA5 (0.60) | HSD17B10GABRA5GABRB2ALDH1A1SMN1; SMN2 | |
| SCHEMBL8445 | 0.83 | MEN1 (0.64) | HSD17B10GABRA5GABRB2ALDH1A1SMN1; SMN2 | |
| SCHEMBL27527998 | 0.83 | GABRA5 (0.51) | HSD17B10GABRA5GABRB2ALDH1A1SMN1; SMN2 | |
| SCHEMBL8313903 | 0.83 | GABRA5 (0.64) | HSD17B10GABRA5GABRB2ALDH1A1SMN1; SMN2 | |
| SCHEMBL12780856 | 0.82 | NOS1 (0.56) | HSD17B10GABRA5GABRB2ALDH1A1SMN1; SMN2 | |
| SCHEMBL10991421 | 0.82 | GABRA5 (0.58) | HSD17B10GABRA5GABRB2ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1631420 | 0.82 | GABRA5 (0.50) | HSD17B10GABRA5GABRB2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101362735-B | Preparation method of ethyl 2-[[(bezyloxy)carbonyl]amido]-4-thiazolyl acetate | SHANDONG JINCHENG PHARMACEUTICAL & CHEMICALS CO LTD | 2011-01-05 | — | — | CN | claimed |
| EP-3717459-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | disclosed |
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-12503466-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2025-12-23 | — | — | US | disclosed |
| EP-3880660-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025048759-A1 | BENZIMIDAZOLE DERIVATIVES AS MPGES-1 INHIBITORS | ICOSYN THERAPEUTICS SAGLIK TEKNOLOJILERI ANONIM SIRKETI (TR) | 2025-03-06 | — | — | WO | disclosed |
| WO-2024140653-A1 | SELECTIVE CDK12/13 INHIBITOR AND APPLICATION THEREOF | 南京圣和药业股份有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-118255746-A | Selective CDK12/13 inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240010645-A1 | Aminothiazole Compounds as Inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2024-01-11 | — | — | US | disclosed |
| EP-4275759-A2 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | Dana-Farber Cancer Institute, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| US-4782147-A | ANTIBIOTIC | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-11-01 | — | — | US | disclosed |
| EP-0053816-B1 | 1-SULFO-2-OXOAZETIDINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1988-05-04 | — | — | EP | disclosed |
| US-4675397-A | MICROBIOCIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-06-23 | — | — | US | disclosed |
| US-4665067-A | BACTERICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-05-12 | — | — | US | disclosed |
| US-4560765-A | USING 183-THIAZOL-4-YL GLYOXYLIC ACID AS INTERMEDIATE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-12-24 | — | — | US | disclosed |
| US-4550105-A | BETA-LACTAMASE INHIBITORS, ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-10-29 | — | — | US | disclosed |
| US-4500716-A | Intermediate products for the preparation of Z-cephalosporins | BAYER AKTIENGESELLSCHAFT (DE) | 1985-02-19 | — | — | US | disclosed |
| EP-0093376-A2 | 1-Sulfo-2-azetidinone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1983-11-09 | — | — | EP | disclosed |
| EP-0053816-A1 | 1-Sulfo-2-oxoazetidine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-06-16 | — | — | EP | disclosed |
| US-4303655-A | MICROBIOCIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503466-B2 | Aminothiazole compounds as inhibitors of CTPS1 | CTPS1, CTPS2, TBXAS1 | HSD17B10 2038/4885GABRA5 4137/4885GABRB2 2961/4885 |
| US-20240010645-A1 | Aminothiazole Compounds as Inhibitors of CTPS1 | CTPS1, CTPS2, TBXAS1 | HSD17B10 2038/4885GABRA5 4137/4885GABRB2 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.